| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
VP Global Regulatory & Quality
1 company
David Chilton Mitchell last filed a Form 4 in March 2017, as VP Global Regulatory & Quality at NGNE. David Chilton Mitchell's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 3,575 shares of NGNE. Net of sales, the NGNE filings show accumulation of 5,175 shares.
David Chilton Mitchell has 5 Form 4 filings on record from January 2015 to March 2017, all as VP Global Regulatory & Quality at Neurogene (NGNE), 2015–2017.
The 5 reported transactions were 3 option or other derivative awards and 2 open-market purchases.
Counted by filing, the open-market trades come to 2 purchases worth about $103K and no sales.
The largest open-market purchase was 3,575 shares of NGNE at an average $17.81 on August 24, 2015, about $64K.
Shares as reported in the last Form 4 for each company; the most recent is from March 2017. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.